Clinical Trial Update: MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2) [Phase 1]

View source ↗

Summary

A Phase 1 trial of MK-6186 (MK6186-007 AM2) in HIV-1 infected patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MK-6186

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 1 | Status: TERMINATED